KIT exon 9 GIST has shorter PFS on imatinib 400 mg vs exon 11. Imatinib 800 mg/day (split...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-KIT-EXON9-GIST |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-GIST |
| Fuentes | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-KIT |
|---|---|
| Variante | inserción del exón 9 (dominio extracelular — ~10% GIST, predominantemente del intestino delgado) |
| Enfermedad | DIS-GIST |
| El nivel de ESCAT | IB |
| Combinaciones recomendadas | imatinib 800 mg/day split BID (1L advanced/metastatic exon 9) |
| Monoterapia contraindicada | imatinib 400 mg/day as 1L for exon 9 (inferior PFS — escalate to 800 mg) |
| Resumen de las pruebas | KIT exon 9 GIST has shorter PFS on imatinib 400 mg vs exon 11. Imatinib 800 mg/day (split 400 mg BID) improves PFS and OS vs 400 mg in this genotype (EORTC-62005 / MetaGIST meta-analysis, Gastrointest Stromal Tumor Meta-Analysis 2010). High dose is standard 1L for exon 9. |
Notas
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST. Adjuvant strategy in high-risk resected exon-9 GIST less established — extended- duration imatinib often considered. Exon 9 GIST predominantly small-bowel primary; extra-gastric origin should prompt KIT exon 9 testing if not already done.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.